Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of hypogonadism
3.2.1.2 Advancements in drug delivery
3.2.1.3 Growing awareness about hypogonadism
3.2.1.4 Expanding aging population
3.2.2 Industry pitfalls and challenges
3.2.2.1 Side effects and risks
3.3 Growth potential analysis
3.4 Pricing analysis, 2024
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Technology landscape
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 Injectables
5.3 Topicals
5.4 Other product types
Chapter 6 Market Estimates and Forecast, By Active Ingredients, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Testosterone cypionate
6.3 Testosterone
6.4 Testosterone enanthate
6.5 Testosterone undecanoate
6.6 Other active ingredients
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 Brick & mortar
7.3 E-commerce
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 AbbVie
9.2 Antares Pharma
9.3 Cipla
9.4 Eli Lilly & Co.
9.5 Endo International
9.6 Ferring Pharmaceuticals
9.7 Halozyme
9.8 Lupin
9.9 Marius Pharmaceuticals
9.10 Pfizer
9.11 Sun Pharmaceutical Industries
9.12 Teva Pharmaceuticals
9.13 Tolmar
